Good morning and welcome to all of our new members, We alerted you to a our new bounce play (NASDAQ: EVFM) this morning and we saw an opening price of...
The Issues With Our FDA and Market News Resources Have Now Been Resolved
Update 10-15-21 this has been resolved. 🙂
FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine
Article Link: FDA Approves Qulipta (atogepant) Oral CGRP Receptor Antagonist for the Preventive Treatment of Migraine NORTH CHICAGO, Ill., ...
FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia
Article Link: FDA Approves Repatha (evolocumab) In Pediatric Patients Age 10 And Older With Heterozygous Familial Hypercholesterolemia THOU...
Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Article Link: Incyte Announces FDA Approval of Jakafi (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD) Jakafi is app...
FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD)
Article Link: FDA Approves Opzelura (ruxolitinib) Cream for the Treatment of Atopic Dermatitis (AD) WILMINGTON, Del.–(BUSINESS WIRE...
FDA Grants Accelerated Approval for Tivdak (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Article Link: FDA Grants Accelerated Approval for Tivdak (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer ...
FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis
Article Link: FDA Approves Byooviz (ranibizumab-nuna), a Biosimilar to Lucentis INCHEON, Korea and CAMBRIDGE, Mass. – September 20, 2021 ...
Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
Article Link: Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Diff...
FDA Approves Exkivity (mobocertinib) for EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer (NSCLC)
Article Link: FDA Approves Exkivity (mobocertinib) for EGFR Exon20 Insertion+ Non-Small Cell Lung Cancer (NSCLC) OSAKA, Japan & CAMBR...
